30% of patients have an aggressive type of this cancer needing urgent treatment, about 70% have slow-growing cancer and can be monitored without immediate treatment.
This new test was developed out of concerns over-treatment was becoming an issue for men with this type of cancer who may not need treatment.
Conclusion: https://bjui-journals.onlinelibrary.wiley.com/doi/10.1002/bco2.474?fbclid=IwY2xjawIJbD1leHRuA2FlbQIxMAABHUSnhz-ugdbis31f1RIiZ29Pfrmoz_JXAWilNVme-L3aFsCA35khswqsMA_aem_30sxxBEWlboKs6aqWleGgA
Biopsy-based MCRS improves risk stratification over standard clinical and pathological information and optimises patient management after diagnosis of prostate cancer.
Lynch Syndrome Ireland 